Background

- Recurrent (more than 3 per year) clinical urinary tract infections (UTI) are problematic for dogs and continual administration of antimicrobial therapy could lead to bacteria becoming resistant. Therefore, the purpose of this trial is to investigate a novel non-antibiotic treatment, asymptomatic bacteriuria (ASB) for recurrent UTIs in dogs.

Participation Requirements

- Dogs that have had more than three (3) UTIs in a single year associated with clinical signs

Procedures

- First visit
  - We will perform a complete physical examination and collect blood, urine and urine culture for analysis.
  - An abdominal ultrasound to look for underlying causes for the recurrent UTIs will be performed. If no underlying causes can be documented, your dog will be sedated, and have a catheter inserted into the urethra. The ASB will be infused into the bladder. After the procedure, your dog will recover at the VMTH and then be discharged to you the same day.
  - Follow-up
    - You will need to bring your dog to the VMTH 1, 7, and 14 days after instillation of the ASB. Furthermore, a final evaluation 2 months later is also required. Urine will be collected at each visit.
    - During the first two weeks, you will need to complete a daily questionnaire regarding your pet's clinical signs. This should take approximately 30-60 seconds to complete.
    - If the treatment does not alleviate your dog's clinical signs, antibiotics will be administered.

Owner Responsibilities

- You will be responsible for keeping the scheduled visits that are assigned to you and completing the questionnaire regarding your pet's urinary tract health. We expect that participation in this clinical trial will require up to 4 visits to the VMTH, but only the first visit will require that your dog stay at the VMTH for at least 4 hours of evaluation.
- You will be responsible for contacting us immediately should you have any concerns about your dog or if your dog has any serious complications.

Benefits

- The study will cover all costs associated with the study; however, if you decide to remove your dog from the study, all further costs related to the presenting problem (recurrent UTI) will your responsibility to cover. If any serious complications occur due to participation in the study, treatment for those complications will be covered by the study.
- We hope that this study will lead to elimination of the clinical signs and discomfort associated with infection, a decrease in the need for antimicrobial drug therapy (and thus selection of drug-resistant bacteria need) after bacteria, and improvement of outcomes for other dogs and possibly humans suffering from recurrent UTIs.